---
reference_id: "PMID:12848964"
title: "Antiphospholipid syndrome: pathogenic mechanisms."
authors:
- Espinosa G
- Cervera R
- Font J
- Shoenfeld Y
journal: Autoimmun Rev
year: '2003'
doi: 10.1016/s1568-9972(02)00144-1
content_type: abstract_only
---

# Antiphospholipid syndrome: pathogenic mechanisms.
**Authors:** Espinosa G, Cervera R, Font J, Shoenfeld Y
**Journal:** Autoimmun Rev (2003)
**DOI:** [10.1016/s1568-9972(02)00144-1](https://doi.org/10.1016/s1568-9972(02)00144-1)

## Content

1. Autoimmun Rev. 2003 Mar;2(2):86-93. doi: 10.1016/s1568-9972(02)00144-1.

Antiphospholipid syndrome: pathogenic mechanisms.

Espinosa G(1), Cervera R, Font J, Shoenfeld Y.

Author information:
(1)Department of Autoimmune Diseases, Institut Clínic d'Infeccions i 
Immunologia, Hospital Clínic, Villarroel 170, 08036 Barcelona, Catalonia, Spain.

Despite the strong association between antiphospholipid antibodies (aPL) and 
thrombosis, the pathogenic role of aPL in the development of thrombosis has not 
been fully elucidated. Proposed pathophysiological mechanisms may be categorized 
into two types. First, aPL may act in vivo by disrupting the kinetics of the 
normal procoagulant and anticoagulant reactions occurring on cell membranes. 
Second, aPL may stimulate certain cells thereby altering the expression and 
secretion of various molecules. In this article, we review the mechanisms by 
which aPL may develop thrombotic events.

DOI: 10.1016/s1568-9972(02)00144-1
PMID: 12848964 [Indexed for MEDLINE]